India's Sun Pharma Wins over Taro with Higher Offer

India's Sun Pharmaceutical Industries has upped the buy-out price for its Israeli unit Taro Pharma by 60%, winning over Taro's board and ending a long battle to gain full control of the U.S. listed drugmaker.

Under the latest offer, which comes a month after Taro rejected an earlier bid, Sun Pharmaceutical will pay $571 million to buy about a third of Taro's 44.5 million shares at $39.50 a share, up from an offer of $24.50 a share.

Mumbai-based Sun Pharma, India's top drugmaker by market value, said in a statement it planned to delist Taro from the New York Stock Exchange once the buy-out process was completed.

Taro said in a statement its board of directors had approved the sweetened offer.

"It's a positive move because this will help Sun Pharma bring Taro to its own levels and also run the U.S. business more efficiently," said Deepak Malik, analyst at brokerage Emkay.

"The price offered is market driven and hence is a fair price," he said.

Sun Pharmaceutical and its affiliates own about 66% of Taro's ordinary shares and 100% of the shares of Taro's founders, representing about 77.5% of the outstanding voting power in Taro.

Sun Pharma last week reported a 59% rise in quarterly net profit at 7.96 billion rupees ($143.9 million) as sales in its key U.S. market surged, helped by a robust performance by Taro.

 

 

 

 

 

 

 

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.